Aclasta licence extended to include use in men

The licence for Aclasta (zoledronate) has been extended to include the treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture.

The recommended dose for the treatment of postmenopausal osteoporosis and osteoporosis in men is a single 5mg intravenous infusion administered once a year.

View Aclasta drug record

Further information: Novartis


Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more